NCT05895994View on ClinicalTrials.gov

Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

February 20, 2025

Study Completion Date

February 20, 2026

Conditions

NeoplasmsHematologic NeoplasmsNeoplasms by SiteHematologic Diseases

Interventions

DRUG

RD13-02 cell infusion

CAR-T cells

Trial Locations (1)

430022

RECRUITING

Union Hospital, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

collaborator

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY

lead

MEI HENG

OTHER

NCT05895994 - Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies | Biotech Hunter | Biotech Hunter